Gold-Catalyzed [2+2] Cyclization of Alkyne-propargylic Pivaloates to Fused Bicyclic Compounds

Chang Ho Oh,* Ahyun Kim

Department of Chemistry, Hanyang University, Sungdong-Gu, Seoul 133-791, Korea Fax +82(2)22990762; E-mail: changho@hanyang.ac.kr Received 3 December 2007

Abstract: We discovered a new and highly convenient gold-catalyzed cyclization of alkyne-propargylic pivaloates leading to fused bicyclic compounds.

Key words: gold, cyclization, pivaloate, catalyst, bicyclic compounds

Recent advances in gold-based alkyne activation led to develop new and efficient catalytic reactions applicable to the synthesis of complex molecules.¹ On the behalf of the excellent alkynophilicity of gold cations, terminal alkynes in the presence of a nucleophile could form gold–carbene complexes.² Internal alkynes are weakly activated enough to react with nucleophiles of alkenes or aldehydes. Phenyl-substituted alkynes, for example, might form weak π complexes which underwent [2+2+2] cycloaddition with a pendent double bond and one double bond in the phenyl ring.³ We became interested in gold-catalyzed chemistry of triynes containing a terminal, an internal (propargylic ester), and a phenyl-conjugated triple bond in the same molecule.

In this context, we recently reported gold-catalyzed cascade cyclization of the triyne 1 to the tricycle 3.⁴ Mechanistically, the allene 2, the initial intermediate from 1 under the gold catalysis, would react with the terminal triple bond to form the gold-bound diene intermediate A, which would subsequently undergo [4+2] cycloaddition to **B**. The further conversion of **B** via demetalation (into **C**) and dehydrogenation afforded the tricycle **3** (Scheme 1). Yet its mechanism and the origin of hydrogen were not clear.

The present conditions toward a triyne 4a, a homologue of 1a, did not afford the expected tricycle, but exhibited a different mode of reactions to give the [3.2.0]-bicyclic system 7a. Herein we wish to report our results on the scope and limitations of this new reaction leading to the [3.2.0] and [4.2.0] bicycles 7 (Scheme 2).⁵ At first, we surveyed the reaction conditions including catalysts, solvent, and the reaction temperatures toward the substrate 4a (Table 1). Sodium tetrachloroaurate (NaAuCl₄) was tested in three different solvents (entries 1-3). While NaAuCl₄ in either dichloromethane at 50 °C or 1,4-dioxane at 80 °C was ineffective, NaAuCl₄ in ethanol catalyzed 4a into the allene intermediate 5a, which was hydrolyzed to the corresponding enone **6a**. The same conversion into enone **6a** was also carried out by AuBr₃ in ethanol at 80 °C (entry 4). Both AuCl/AgSbF₆ and AuCl₃/ AgSbF₆ as cooperative catalysts in dioxane at 50 °C led to decomposition of 4a. To our delight, 5 mol% AuCl(PPh₃) with $AgSbF_6$ as a cocatalyst in 1,2-dichloroethane (DCE) at room temperature converted 4a into the bicyclo[3.2.0] compound 7a in 72% yield (entry 7). Finally, we tested PtCl₂ as a catalyst but found to be ineffective for this reaction (entry 8). Next, we tested other structurally similar



Scheme 1

SYNLETT 2008, No. 5, pp 0777–0781 Advanced online publication: 26.02.2008 DOI: 10.1055/s-2008-1032110; Art ID: Y02107ST © Georg Thieme Verlag Stuttgart · New York



Scheme 2

Table 1 Cyclization of 4a under Various Conditions

Entry	Catalyst (5 mol%)	Solvent	Temp (°C)	Time (h)	Product (yield, %)
1	NaAuCl ₄	CH_2Cl_2	50	5	NR
2	NaAuCl ₄	dioxane	80	5	NR
3	NaAuCl ₄	EtOH	80	0.5	6a (75)
4	AuBr ₃	EtOH	80	0.5	6a (74)
5	AuCl/AgSbF ₆	dioxane	50	15	dec.
6	AuCl ₃ /AgSbF ₆	dioxane	50	15	dec.
7	AuCl(PPh ₃)/AgSbF ₆	DCE	25	15	7a (72)
8	PtCl ₂	toluene	100	15	NR

substrates (**4b**–**g** and **4h**–**j**) under the optimized conditions described in entry 7 in Table 1 (Table 2).⁶

The substrates **4b–g** were smoothly transformed to the [3.2.0] bicycles **7b–g** in good yields. Substrate **4b**, possessing 6-phenylhex-1-ynyl at the R¹ position and phenyl group at the R² position furnished the desired product **7b** in 81% yield. The reactions proceeded smoothly, when the phenyl group (**4c**,**d**) and naphthyl group (**4e**,**f**) were located at the R² position, affording **4c–f** in 72–81% yield. Notably, the substrate **4g** containing a cyclohexyl ring at the R² position was successfully cyclized to **7g** in 72% yield.

The present conditions were successfully applied to the substrates **4h**–**j** affording bicyclo[4.2.0] compounds **7h**, **7i**, and **7j** in 65%, 55%, and 75% yields, respectively.

Next, we have extended further this reaction to two alkyne-pivaloate groups in a molecule linked by a phenyl group to obtain the corresponding dimeric bicycles for useful building blocks (Scheme 3). Both substrates **4k** and

 Table 2
 Gold(I)-Catalyzed Cyclization of Alkyne-pivaloates 4 to Bicyclo[m.2.0] Compounds 7 (Figure 1)

Substrates	Temp (°C)	Time (h)	Product	Yield (%) ^a
R ¹				
4b	80	15	7b	81
4c	40	1	7c	75
4d	40	1	7d	80
4 e	25	1	7e	72
4f	25	1.5	7f	80
4g	25	2	7g	72
4h	40	2.5	7h	65
4i	40	15	7i	55
4j	25	15	7j	75

 $^{\rm a}$ All reactions were carried out 5 mol% of AuCl(PPh_3) and AgSbF_6 in DCE.

41 were prepared and cyclized under the present conditions to give the expected products **7k** and **7l** in 85% and 83% yields, respectively. Surprisingly, these cyclizations **4k,l** to **7k,l** seemed to proceed more easily in comparison to substrates **4a**–**j**; this might imply that the electron-withdrawing effect by the first cyclization might facilitate the second cyclization.

A possible mechanism for gold-catalyzed cyclization of alkyne-proparglic pivaloate 4a to 7a is proposed (Scheme 4).



Scheme 3

Figure 1

Coordination of gold(I) to propargylic alkyne induced migration of the pivaloate to give the allene intermediate **A**. The allene **A** was expected to undergo condensation with one of the gold-activated triple bonds, path a and b. The isolation of **7a** and no formation of **3a** might suggest the intermediacy of **C** via path b. Intermediate **C** could eliminate pivaloic acid by addition of H_2O to form **D**. Finally, cyclization of **D** into **E** might be postulated, although such a cyclization is not known. Instead, the allene **A** could be directly cycloadded via a [2+2] pathway to give the intermediate **F**, which would afford the isolated product **7a** upon hydrolysis.

In conclusion, we discovered a highly convenient goldcatalyzed cyclization of alkyne-propargylic pivaloates leading to [m.2.0] bicyclic compounds, that could provide an easy access to valuable building blocks for polycyclic compounds.



Scheme 4

Acknowledgment

We wish to acknowledge the financial support of Korea Science and Engineering Foundation (R01-2007-000-20315-0).

References and Notes

- For reviews, see: (a) Hashmi, A. S. K.; Hutchings, G. J. Angew. Chem. Int. Ed. 2006, 45, 7896. (b) Gorin, D. J.; Toste, F. D. Nature (London) 2007, 446, 395. (c) Jiménez-Núñez, E.; Echavarren, A. M. Chem. Commun. 2007, 333.
- (2) (a) Huang, X.; Zhang, L. J. Am. Chem. Soc. 2007, 129, 6398. (b) Nieto-Oberhuber, C.; Pérez-Galán, P.; Herrero-Gómez, E.; Lauterbach, T.; Rodriguez, C.; López, S.; Bour, C.; Rosellon, A.; Cárdenas, D. J.; Echavarren, A. M. J. Am. Chem. Soc. 2008, 130, 269. (c) Luo, T.; Schreiber, S. L. Angew. Chem. Int. Ed. 2007, 46, 8250. (d) Johansson, M. J.; Gorin, D. J.; Staben, S. T.; Toste, F. D. J. Am. Chem. Soc. 2005, 127, 18002. (e) Luzung, M. R.; Markham, J. P.; Toste, F. D. J. Am. Chem. Soc. 2005, 127, 18002. (e) Luzung, M. R.; Markham, J. P.; Toste, F. D. J. Am. Chem. Soc. 2005, 127, 18002. (e) Luzung, M. R.; Markham, J. P.; Toste, F. D. J. Am. Chem. Soc. 2005, 127, 18002. (e) Luzung, M. R.; Markham, J. P.; Toste, F. D. J. Am. Chem. Soc. 2004, 126, 11806. (g) Zhang, L.; Kozmin, S. A. J. Am. Chem. Soc. 2005, 127, 6963. (h) C. Nieto-Oberhuber, S.; López, A. M.; Echavarren, A. M. J. Am. Chem. Soc. 2005, 127, 6178. (i) Fürstner, A.; Hannen, P. Chem. Commun. 2004, 2546.
- (3) (a) Mézailles, N.; Ricard, L.; Gagosz, F. Org. Lett. 2005, 7, 4133. (b) Nieto-Oberhuber, C.; Muñoz, M. P.; López, S.; Jiménez-Núñez, E.; Nevado, C.; Herrero-Gómez, E.; Raducan, M.; Echavarren, A. M. Chem. Eur. J. 2006, 12, 1677.
- (4) Oh, C. H.; Kim, A. New J. Chem. 2007, 31, 1719.
- (5) For Au-catalyzed [2+2] cyclization, see: (a) Couty, S.; Meyer, C.; Cossy, J. *Angew. Chem. Int. Ed.* **2006**, *45*, 6726.
 (b) Luzung, M. R.; Mauleon, P.; Toste, F. D. J. Am. Chem. Soc. **2007**, *129*, 12402.
- (6) Typical Experimental Procedure for Cyclization of 4a to 7a

In a 5 mL new test tube were placed AuCl(PPh₃) (7.0 mg, 14.0 μ mol, 5 mol%) and AgSbF₆ (4.8 mg, 14 μ mol) and added dried DCE (1.0 mL) under argon atmosphere. After

Synlett 2008, No. 5, 777–781 © Thieme Stuttgart · New York

being stirred for 10 min at 0 °C, a DCE solution (0.5 mL) of diyne-propargylic pivaloate **4a** (101.0 mg, 0.28 mmol) was added. The resulting mixture was stirred for 15 h at r.t. and the reaction was periodically monitored by TLC. Upon completion, the solvent was removed under vacuum and the crude product was subjected to flash column chromatography (SiO₂, *n*-hexane–EtOAc = 30:1) to afford the pure product **7a** as a colorless oil. All new compounds were fully characterized by ¹H NMR, ¹³C NMR, IR, and HRMS (ESMS).

Compound 7a: IR (NaCl): 3301, 3064, 2940, 2869, 1707, 1671, 1491, 1287 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): $\delta =$ 8.07-8.04 (m, 2 H), 7.42-7.37 (m, 3 H), 3.47 (q, J = 4.0 Hz, 1 H), 3.40 (q, J = 4.0 Hz, 1 H), 2.68–2.49 (m, 2 H), 2.22 (td, *J* = 7.0, 3.2 Hz, 2 H), 1.95 (t, *J* = 2.4 Hz, 1 H), 1.83–1.68 (m, 5 H), 1.66–1.54 (m, 3 H), 1.49–1.38 (m, 3 H). ¹³C NMR (100 MHz, CDCl₃): $\delta = 197.13, 155.44, 136.26, 132.49, 130.25,$ 128.93, 128.35, 84.19, 68.46, 43.75, 43.28, 40.06, 28.01, 26.31, 26.07, 23.16, 22.72, 18.35. HRMS: m/z calcd for C₂₀H₂₂ONa⁺: 301.3779; found: 301.3787. Compound 7b: IR (NaCl): 3059, 3030, 2931, 2853, 2225, 1736, 1670, 1560, 1175 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): $\delta = 8.06 - 8.04 \text{ (m, 2 H)}, 7.39 - 7.37 \text{ (m, 5 H)}, 7.28 - 7.24 \text{ (m, 3)}$ H), 3.45 (q, J = 3.6 Hz, 1 H), 3.39 (q, J = 3.6 Hz, 1 H), 2.71-2.52 (m, 2 H), 2.44 (t, J = 7.6 Hz, 2 H), 1.86–1.77 (m, 4 H), 1.73–1.54 (m, 6 H), 1.48–1.38 (m, 2 H). $^{13}\mathrm{C}$ NMR (100 MHz, CDCl₃): $\delta = 197.23, 155.39, 136.35, 132.55, 131.55,$ 130.23, 128.94, 128.35, 128.14, 127.49, 123.97, 89.87, 80.89, 43.78, 43.33, 40.17, 28.33, 26.34, 26.09, 23.18, 22.97, 19.35. HRMS: *m/z* calcd for C₂₆H₂₆ONa⁺: 377.4733; found: 377.4778. Compound 7c: IR (NaCl): 3065, 3030, 2945, 2857, 2247, 1797, 1634, 1490, 1228, 1172 cm⁻¹. ¹H NMR (400 MHz, $CDCl_3$): $\delta = 7.88$ (d, J = 3.8 Hz, 2 H), 7.57–7.54 (m, 2 H), 7.49 (t, J = 7.2 Hz, 1 H), 7.38 (t, J = 7.2 Hz, 2 H), 7.28–7.23 (m, 3 H), 3.64–3.56 (m, 2 H), 1.87–1.78 (m, 2 H), 1.74–1.63 (m, 2 H), 1.52–1.46 (m, 1 H), 1.42–1.32 (m, 1 H). ¹³C NMR $(100 \text{ MHz}, \text{CDCl}_3): \delta = 191.46, 153.85, 138.08, 136.24,$ 132.54, 132.40, 129.54, 128.94, 128.69, 128.39, 128.19,

152.34, 152.40, 129.34, 128.94, 128.09, 128.39, 128.19, 45.69, 44.53, 26.49, 26.27, 23.29 29. HRMS: *m/z* calcd for

C₂₀H₁₈ONa⁺: 297.3461; found: 297.3462. Compound 7d: IR (NaCl): 3066, 2956, 2933, 2869, 2350, 1716, 1655, 1540, 1458 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): $\delta = 8.06 - 8.04 \text{ (m, 2 H)}, 7.40 - 7.37 \text{ (m, 3 H)}, 3.47 - 3.38 \text{ (m, 2 H)}$ H), 2.64–2.46 (m, 2 H), 1.84–1.77 (m, 2 H), 1.74–1.56 (m, 5 H), 1.49–1.33 (m, 5 H), 0.92 (t, J = 7.2 Hz, 3 H). ¹³C NMR $(100 \text{ MHz}, \text{CDCl}_3)$: $\delta = 197.87, 155.07, 136.52, 132.57,$ 130.15, 128.92, 128.32, 43.70, 43.34, 40.41, 26.32, 26.09, 25.80, 23.17, 22.43, 13.96. HRMS: m/z calcd for C₁₈H₂₂ONa⁺: 277.3559; found: 277.3554. Compound 7e: IR (NaCl): 3058, 2942, 2859, 2252, 1747, 1636, 1578, 1445, 1334 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ = 7.96 (d, J = 8 Hz, 1 H), 7.74–7.69 (m, 2 H), 7.57 (d, J = 7.2 Hz, 2 H), 7.39–7.28 (m, 4 H), 6.93 (t, J = 7.6 Hz, 2 H), 3.86 (q, J = 3.6 Hz, 1 H), 3.68 (q, J = 3.6 Hz, 1 H), 2.31– 2.27 (m, 1 H), 1.89–1.65 (m, 2 H), 1.86–1.77 (m, 2 H), 1.63– 1.51 (m, 2 H), 1.44–1.34 (m, 2 H). $^{\rm 13}C$ NMR (100 MHz, $CDCl_3$): $\delta = 191.50, 154.83, 139.20, 137.60, 133.31, 131.96,$ 131.86, 130.83, 129.02, 128.95, 128.68, 128.20, 127.60, 127.01, 126.24, 125.79, 125.23, 124.89, 48.74, 45.71, 26.85, 25.58, 23.54. HRMS: *m/z* calcd for C₂₄H₂₀ONa⁺: 347.4042; found: 347.4042. Compound 7f: IR (NaCl): 3056, 2956, 2930, 2858, 1655, 1506, 1460, 1391, 1198, 1026 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ = 7.97–7.84 (m, 3 H), 7.52–7.37 (m, 4 H), 3.62– 3.50 (m, 2 H), 2.23-2.08 (m, 2 H), 2.04-2.01 (m, 1 H), 1.84-1.76 (m, 2 H), 1.61–1.58 (m, 2 H), 1.51–1.41 (m, 1 H), 1.38– 1.26 (m, 4 H), 0.59 (t, J = 7.6 Hz, 3 H). ¹³C NMR (100 MHz, $CDCl_3$): $\delta = 198.22, 155.35, 141.22, 133.55, 132.77, 130.74,$ 128.86, 128.51, 126.48, 126.20, 125.81, 125.41, 125.13, 48.87, 43.80, 39.96, 26.37, 26.23, 24.96, 23.47, 22.16,

13.52. HRMS: m/z calcd for $C_{22}H_{24}ONa^+$: 327.4146; found: 327.4145.

Compound **7g**: IR (NaCl): 3032, 2936, 2863, 2246, 1769, 1649, 1507, 1338 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ = 7.89–7.86 (m, 2 H), 7.54–7.47 (m, 3 H), 7.39–7.35 (m, 2 H), 7.26–7.24 (m, 1 H), 3.41–3.30 (m, 2 H), 2.06–1.96 (m, 1 H), 1.87–1.47 (m, 7 H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.65, 157.03, 139.83, 138.07, 133.36, 132.40, 129.37, 128.86, 128.53, 128.41, 128.22, 39.68, 38.60, 24.10, 23.51, 18.82, 18.70. HRMS: *m/z* calcd for C₂₁H₂₀ONa⁺: 311.3721; found: 311.3725.

Compound **7h**: IR (NaCl): 2961, 2860, 2255, 1794, 1714 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): $\delta = 8.01-7.98$ (m, 2 H), 7.40–7.37 (m, 3 H), 3.19 (q, J = 6.0 Hz, 1 H), 3.13 (q, J = 5.6 Hz, 1 H), 2.62–2.43 (m, 2 H), 1.97–1.89 (m, 2 H), 1.78–1.68

(m, 2 H), 1.27–1.22 (m, 1 H). ¹³C NMR (100 MHz, CDCl₃): $\delta = 198.18, 158.27, 140.18, 133.32, 129.95, 128.78, 128.31,$ 40.80, 37.91, 37.56, 25.74, 23.94, 23.81, 22.43, 18.85, 18.70, 13.94. HRMS: *m/z* calcd for C₁₉H₂₄ONa⁺: 291.3824; found: 291.3830. Compound 7i: IR (NaCl): 3051, 2905, 2322, 1745, 1678, 1487, 1145 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): $\delta = 8.04$ -8.02 (m, 2 H), 7.39–7.37 (m, 3 H), 3.46 (q, J = 3.6 Hz, 1 H), 3.41 (q, J = 3.6 Hz, 1 H), 2.69–2.64 (m, 1 H), 1.86–1.77 (m, 5 H), 1.74–1.68 (m, 2 H), 1.66–1.59 (m, 1 H), 1.50–1.41 (m, 3 H), 1.34–1.21 (m, 5 H). ¹³C NMR (100 MHz, CDCl₃): $\delta =$ 201.37, 155.99, 136.40, 132.64, 130.11, 128.85, 128.30, 47.53, 43.66, 43.56, 29.13, 28.13, 26.62, 26.19, 25.97, 25.87, 25.57, 23.18. HRMS: *m/z* calcd for C₂₀H₂₄ONa⁺: 303.3932; found: 303.3930. Compound 7j: IR (NaCl): 3067, 3032, 2863, 2246, 1769, 1649, 1652, 1507, 1338 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): $\delta = 8.05 - 8.03$ (m, 2 H), 7.43-7.41 (m, 3 H), 7.37-7.35 (m, 1 H), 7.23–7.15 (m, 2 H), 7.11–7.09 (m, 1 H), 4.21 (d, J = 4.8 Hz, 1 H), 3.79 (t, J = 4.8 Hz, 1 H), 2.61–2.49 (m, 2 H), 2.37– 2.30 (m, 2 H), 1.65–1.50 (m, 2 H), 1.46–1.35 (m, 2 H), 1.30– 1.21 (m, 2 H), 0.84 (t, J = 7.2 Hz, 3 H). ¹³C NMR (100 MHz, $CDCl_3$): $\delta = 197.73, 155.56, 139.72, 137.17, 136.27, 132.32,$ 130.51, 130.02, 129.29, 129.00, 128.91, 128.80, 128.69, 128.60, 126.58, 126.39, 43.16, 41.42, 39.84, 26.48, 25.67, 39.84, 26.48, 25.67, 25.41, 22.53, 14.12. HRMS: m/z calcd for C₂₃H₂₄ONa⁺: 339.4253; found: 339.4254. Compound 7k: IR (NaCl): 3065, 2949, 2845, 2358, 2249, 1728, 1634, 1598, 1579, 1501, 1446, 1289 cm⁻¹. ¹H NMR $(400 \text{ MHz}, \text{CDCl}_3): \delta = 8.05 \text{ (s, 4 H)}, 3.46 \text{ (q, } J = 3.2 \text{ Hz}, 2$ H), 3.40 (q, J = 4 Hz, 2 H), 2.66–2.46 (m, 4 H), 1.80 (td, *J* = 13.6, 5.2 Hz, 4 H), 1.72–1.57 (m, 8 H), 1.47–1.30 (m, 8 H), 0.92 (t, J = 7.2 Hz). ¹³C NMR (100 MHz, CDCl₃): $\delta =$ 197.79, 154.25, 137.53, 133.82, 128.86, 43.68, 43.54, 40.47, 29.68, 26.35, 25.81, 23.16, 22.43, 13.98. HRMS: m/z calcd for $C_{30}H_{38}O_2Na^+$: 453.6107; found: 453.6104. Compound 71: IR (NaCl): 2955, 2859, 2357, 1746, 1667, 1588, 1504, 1457, 1177 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ = 7.87 (d, J = 7.6 Hz, 4 H), 7.52–7.36 (m, 10 H), 3.62 (q, J = 3.2 Hz, 2 H), 3.54 (q, J = 3.6 Hz, 2 H), 1.82–1.62 (m, 8 H), 1.41–1.31 (m, 4 H). ¹³C NMR (100 MHz, CDCl₃): $\delta =$ 191.29, 137.31, 133.29, 128.90, 128.53, 128.47, 120.62, 45.92, 44.43, 26.48, 26.27, 23.27. HRMS: m/z calcd for C₃₄H₃₀O₂Na⁺: 493.5900; found: 493.5889.

(m, 2 H), 1.66–1.58 (m, 3 H), 1.57–1.42 (m, 4 H), 1.39–1.30

Copyright of Synlett is the property of Georg Thieme Verlag Stuttgart and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.